Hologic manufactures proprietary products for the healthcare needs of women... Show more
Be on the lookout for a price bounce soon.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HOLX advanced for three days, in of 311 cases, the price rose further within the following month. The odds of a continued upward trend are .
HOLX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 214 cases where HOLX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for HOLX moved out of overbought territory on December 16, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on December 23, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HOLX as a result. In of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HOLX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. HOLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.292) is normal, around the industry mean (9.534). P/E Ratio (29.920) is within average values for comparable stocks, (167.335). Projected Growth (PEG Ratio) (1.647) is also within normal values, averaging (2.546). HOLX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (4.134) is also within normal values, averaging (112.419).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HOLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
a manufacturer of diagnostics products, medical imaging systems and surgical products
Industry PharmaceuticalsOther
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IEV | 68.76 | 0.11 | +0.16% |
| iShares Europe ETF | |||
| MMCA | 21.85 | N/A | +0.02% |
| NYLI MacKay California Muni Intmdt ETF | |||
| MARO | 8.28 | -0.01 | -0.12% |
| Yieldmax Mara Option Income Strategy ETF | |||
| PMO | 10.39 | -0.07 | -0.67% |
| Putnam Municipal Opportunities Trust | |||
| BITU | 22.01 | -5.95 | -21.28% |
| ProShares Ultra Bitcoin ETF | |||
A.I.dvisor indicates that over the last year, HOLX has been loosely correlated with ZBH. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if HOLX jumps, then ZBH could also see price increases.
| Ticker / NAME | Correlation To HOLX | 1D Price Change % | ||
|---|---|---|---|---|
| HOLX | 100% | -0.05% | ||
| ZBH - HOLX | 44% Loosely correlated | -0.41% | ||
| RVTY - HOLX | 41% Loosely correlated | -0.19% | ||
| BDX - HOLX | 41% Loosely correlated | -0.54% | ||
| WAT - HOLX | 39% Loosely correlated | -0.24% | ||
| QGEN - HOLX | 39% Loosely correlated | -0.96% | ||
More | ||||
| Ticker / NAME | Correlation To HOLX | 1D Price Change % |
|---|---|---|
| HOLX | 100% | -0.05% |
| Pharmaceuticals category (375 stocks) | 33% Loosely correlated | +0.29% |
| Pharmaceuticals: Other category (102 stocks) | 31% Poorly correlated | +0.21% |